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Abstract 
Analysis of the degradation products from two proteins, the insulin B-chain and human hemoglobin, generated by archaebacterial Thermoplasma 
acidophilum 20 S proteasomes, revealed an unexpectedly broad specificity. In spite of the vast number of different peptides found, they fell into a 
rather narrow size range. This suggests that a molecular uler exists which determines the length of the cleavage products. 
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1. Introduction 
Proteasomes, also known as the multicatalytic pro- 
teinase complex (EC 3.4.99.46), play a key role in the 
degradation of abnormal proteins and of short-lived reg- 
ulatory proteins, both in the cytosol and in the nucleus 
[l-3]. Moreover, they are implicated in antigen presenta- 
tion, generating peptides which associate with major his- 
tocompatibility complex (MHC) class I molecules [4-61. 
The ATP-dependent degradation of ubiquitinated [7-91 
and of certain non-ubiquitinated proteins [lo] is linked 
to the 26 S proteasome (Zt4, -2000 kDa) while the 20 S 
proteasome (M, -700 kDa), which constitutes the pro- 
teolytic core of the 26 S complex [ 11,121, degrades only 
unfolded proteins [ 131. 
The eukaryotic 20 S proteasome is a ubiquitous, 
highly conserved barrel-shaped complex [14,15] compris- 
ing of up to 14 different subunits. Proteasomes indistin- 
guishable on the quarternary structure level from eukar- 
yotic proteasomes are found in the archaeon Thermo- 
plasma [16]. They are made of only two different sub- 
units, a and p, which occur in an a14& stoichiometry; 
all hitherto available amino acid sequences of eukaryotic 
proteasomes can be related to either the a or /I subunit 
of the Thermoplasma urproteasome [17]. Because of its 
relative simplicity the Thermoplasma proteasome has a 
pivotal role in advancing our understanding of the struc- 
ture of this large protein complex [l&20]. 
In this communication we describe experiments using 
recombinant Thermoplusma proteasomes [21] for the 
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degradation of two protein substrates, namely the insulin 
B-chain and human hemoglobin. Whereas oxidized insu- 
lin B-chain can be used as a substrate for the 20 S pro- 
teasome without pretreatment [22], native hemoglobin is 
not degraded by the Thermoplasma proteasome. At least 
partial unfolding is required, accomplished e.g. through 
phenylhydrazine treatment or hydrogen peroxide-medi- 
ated oxidation. Alternatively, pre-incubation with ubi- 
quitin can be used to render hemoglobin susceptible to 
degradation [23]: ubiquitin appears to exert a chaotropic 
effect upon associating with proteins; it is unclear 
whether or not this effect has any physiological rele- 
vance. In the context of our experiments, the use of 
ubiquitin for conditioning the hemoglobin has the practi- 
cal advantage that it does not chemically alter the con- 
stituent amino acids. 
2. Materials and methods 
2.1. Isolation, purification and activity assay of proteasomes 
Recombinant Thermoplasma acidophilum proteasomes, expressed in 
Escherichia coli [21], were isolated and purified as described previously 
[19]. Routinely, activity assays of isolated proteasomes were performed 
by using Sue-Leu-Leu-Val-Tyr-NMec (Bachem Biochemica GmbH, 
Heidelberg, Germany), as described earlier [24]. 
2.2. Degradation of substrate proteins 
Bovine insulin B-chain and human hemoglobin-A,, (both from Sigma 
Chemie GmbH, Deisenhofen, Germany) were degraded with recombi- 
nant Thermoplasma acidophilum proteasomes, expressed in Escherichia 
coli and purified as described earlier [21]. Reaction mixtures contained 
in a volume of 1 ml: 1 mg oxidized bovine insulin B-chain, 50 mM 
Tris-HCI (pH 7.5) and 5 ,ug of recombinant Thermoplasma acidophilum 
proteasomes. Following incubation at room temperature for 24 h, the 
samples were analysed by LCYMS. For the degradation of human he- 
moglobin-A,, a 1 mg sample was incubated with 1 mg ubiquitin from 
bovine red blood cells (Sigma Chemie GmbH, Deisenhofen) to render 
it degradable [23], 50 mM Tris-HCl (pH 7.5) and 5pg of Thermoplasma 
acidophilwn proteasomes. After an incubation period of 24 h at 6O”C, 
the total peptide mixture was analyzed by LCIMS. After an incubation 
time of 24 h further addition of fresh proteasomes did not cause any 
further degradation, whereas the degradation of added insulin B-chain 
indicated the still extant activity of the proteasomes. 
0014-57931941S7.00 0 1994 Federation of European Biochemical Societies. All rights reserved. 
SSDI 0014-5793(94)00665-I 
T Wenzel et al. IFEBS Letters 349 (1994) 205-209 
2.3. Liquid chromatography and mass spectrometry 3. Results and discussion 
The degradation products were separated by reversed-phase chrom- 
atography (System 1090, Hewlett Packard, Waldbronn, Germany) 
using a 2 mm column (C18, LiChroCart 125-2, Merck, Darmstadt, 
Germany). The solvent system used was 0.1% (v/v) trifluoroacetic acid 
in water (solvent A) and 0.1% trifluoroacetic acid in acetonitrile (sol- 
vent B). A gradient from 0 to 60% B was performed in 70 min and from 
60% to 90% B in 15 min at a flow rate of 0.3 ml/min. In both cases the 
degradation of the substrate was almost complete. Ubiquitin remained 
undegraded. Mass spectrometry (B) was performed on-line (LCIMS) 
by coupling of chromatography (SMART-System, Pharmacia, 
Freiburg, Germany) to an atmospheric pressure ionization source (ion 
spray) fitted to tandem quadrupole instrument API III (Sciex, 
Thornhill, Ont., Canada). The column and the solvent system for the 
reversed phase separation was the same as described above. The gradi- 
ent from 0% to 60% B was performed in 150 min and from 60% to 90% 
B in 50 min at a flow rate of 20 pl/min. Each scan was acquired over 
the range m/z 3.50-2000 using a step of 0.2 units, a dwell time of 0.5 ms. 
The molecular masses of peptides were obtained as single ions or were 
calculated from the m/z peaks in the charge distribution profiles of the 
multiply charged ions [25,26]. Amino acids or dipeptides could not be 
detected by this method; it is also impossible to calculate the exact 
amount of the derived peptides. 
2.4. Sequence analysis of degradation products 
For this purpose fractions were collected and sequence analysis of the 
derived peptides were performed using a 477 A sequencer model from 
Applied Biosystems (Foster City, CA). 
2.5. Analysis ofjkee amino acids 
Ninhydrine-amino acid analysis was performed on a Beckman 
(Munchen. Germanv) 6300 Amino acid analvzer accordine to the in- 
The degradation products were analysed by reversed- 
phase chromatography in conjunction with mass spec- 
trometry and N-terminal sequencing. With both proteins 
a surprisingly large number of different peptides was 
generated. Most of the peaks in the reversed-phase chro- 
matograms (Fig. 1) contained more than one peptide 
species. For the insulin B-chain we unambiguously iden- 
tified 44 different peptides either by mass spectrometry 
alone or combined with N-terminal sequencing. In the 
case of human hemoglobin, the number of peptide spe- 
cies was >80. Of the 29 peptide bonds in the insulin 
B-chain only six (Phe’-Val’, Asn’-Gln4, Cys’-Glys, 
Tyr16-Leu”, Glu2’-Arg”, Pro28-Lys29) were not cleaved. 
This implies that contrary to conclusions drawn from 
experiments using synthetic peptide substrates, suggest- 
ing that the Thermoplasma proteasome is exclusively a 
‘chymotrypsin-like’ proteinase [ 161, it is essentially a 
non-specific endopeptidase. Therefore, our results cast 
some doubt on the usefulness of assays based on small 
peptide substrates for characterising the various prote- 
olytic activities associated with proteasomes [27], or for 
providing hints as to the nature of the active site(s), 
structions of the manufacturer. 6 nmol of the starting material were 
applied after 24 h. 
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which continues to be an enigma. 
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Fig. I. Reverse-phase separation of the peptides derived from the oxidized bovine insulin B-chain (Al) and human hemoglobin-A, (A2) by digestion 
with Thermoplasma proteasomes, and corresponding mass spectrometric analysis (B). Bl shows a typical Total Ion Current of the derived peptides 
from the insulin B-chain and B2 and B3 two selected mass spectra of the peaks marked in Bl with asterisks. 
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Fig. 2. Degradation of the oxidized bovine insulin B-chain by Thermoplasma acidophilum proteasomes. The sequence is represented in single letter 
code and all the cleavage sites detected are marked by arrows. Lines represent, regardless of their relative abundance, the peptides identified by mass 
spectrometry (Fig. I), complemented, when necessary, by N-terminal sequencing. 
In terms of the evolution of the proteasome, the pres- 
ent data make it unlikely that with the diversification of 
the 01- and B-type subunits, several distinct proteolytic 
activities have been added to a chymotryptic activity of 
the ‘urproteasome’. The data rather suggest that the mo- 
lecular antecedant was a non-specific proteinase and that 
the diversification which followed multiple gene duplica- 
tion events allowed for some functional fine tuning, 
either by changing the active site or the substrate binding 
region. Subunit substitutions, such as the incorporation 
of the MHC-encoded LMP 2 and LMP 7 subunits upon 
y-interferon stimulation, allow further modulations of 
the activity and thus can favour the generation of more 
specific peptide species, as observed [28,29]. 
Notwithstanding the broad specificity of the Thermo- 
plasma proteasome, the peptides generated fell into a 
surprisingly narrow size range. With the insulin B-chain, 
hepta-, octa- and nonapeptides constituted 46% of the 
total peptides and with hemoglobin, 45%. Only 14% of 
the insulin B-chain and only 5% of the hemoglobin de- 
rived peptides were longer than decapeptides. If peptides 
of a certain length are cut out of an unfolded polypeptide 
chain in a more or less random fashion, inevitably some 
‘odds and ends’ will be produced. Only small amounts 
of amino acids have been detected. With 6 nmol starting 
material 360 pmol of free amino acids were found, 
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Fig. 3. Histogram of the length distribution of all identified peptides 
derived from the oxidized bovine insulin B-chain and from human 
hemoglobin-A,. The graphs do not take into account the differences in 
the relative abundance of a given peptide. 
1. c 
Insulin B-chain 
Hemoglobin 
a 
‘,. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Length: Number of 
Amino Acid Residues 
208 i? Wenzel et al. I FEBS Letters 349 (1994) 205-209 
b 
a 
Fig. 4. Schematic illustration of the molecular ruler hypothesis. Left: model showing the subunit arrangement in the Thermoplasma proteasome. Four 
seven-membered rings collectively form a barrel-shaped complex. The a-subunits (dark) form the two outer rings or discs, whereas the /?-subunits 
(light) make up the inner pair of rings. The B-rings are rotated by about 25” with respect to the a-rings [14,15]. Eukaryotic proteasomes have the 
same quarternary structure and the various a- and B-type subunits occupy positions equivalent to the a- and /I-subunits of the Thermoplasma 
proteasome. Right: the Thermoplasma proteasome seen ‘end-on’; for the sake of clarity some a-subunits have been removed. At present, it is neither 
known which amino acids are involved in the catalytic mechanism nor where the catalytic sites are located in the structure. There is circumstantial 
evidence that the B-subunits carry the active sites (e.g. LMP 2 and LMP 7 are p-type subunits); on the other hand only fully assembled proteasomes 
appear to have proteolytic activity indicating that the interface of the a- and/I-subunits has a critical role in function. Regardless of these uncertainties 
the model allows to obtain an estimate of the minimum and maximum distance between the multiple active sites, symbolized by arrow-heads. The 
maximum distance b = 4.2 nm places them at the periphery, the minimum distance c = 2 nm places them near the surface of the inner cavity. The 
diameter of the proteasome a is approximately 11.5 nm. The molecular ruler hypothesis suggests that either two active sites act in concert, thus excising 
peptides of a certain length from a polypeptide chain, or that peptides must have a certain length in order to bind strongly enough to an extended 
binding groove; this too could define a lower length limit for the degradation of peptides. 
mainly alanine. This rules out that the Thermoplasma 
proteasome has an exopeptidase activity. 
Closer inspection of the peptides derived from the in- 
sulin B-chain (Fig. 2) revealed that most of the shorter 
peptides (~7mers) originated from the N-terminal re- 
gion, while the longer peptides (> 10mers) corresponded 
predominantly to C-terminal sequences. Such ‘edge ef- 
fects’ may be taken as an indication that regions being 
located upstream or downstream of the scissile bond 
affect substrate binding. In agreement with this, the 
larger of the two proteins, hemoglobin, yielded a length 
distribution histogram (Fig. 3) with a smaller half-width. 
The size distribution of the peptides generated by the 
Thermoplasma proteasome suggests that some kind of 
a ‘molecular ruler’ exists which determines their length. 
The provision of a molecular ruler in a multisubunit 
complex is not without precedent: for the fatty acid syn- 
thetase it was inferred from an analysis of fatty acid 
chain lengths that an intrinsic ruler controls chain termi- 
nation [30]. With the proteasome it is tempting to put 
forward the hypothesis that it is the distance between 
multiple active sites which determines the length of the 
degradation products (Fig. 4). This hypothesis assumes 
that a stretch of the unfolded polypeptide chain of the 
substrate protein binds to an extended groove. Since only 
the assembled proteasome complex appears to have en- 
zymatic activity it is conceivable that this binding groove 
is located at the interface of the a- and /?-subunits. With 
two active sites acting in concert, peptides of a defined 
length could be excised from a polypeptide chain 
stretched out along the binding groove. 
It is unclear at present precisely where the active sites 
are located. It is clear however, from the structure and 
simple geometric considerations that the largest possible 
distance between active sites is 4.2 nm. Assuming that the 
subunits are ideal spheres, the smallest distance is ap- 
proximately 2 nm, placing the subunits close to the inner 
surface of a hollow cylinder. With more wedge-shaped 
subunits the active sites would move closer towards the 
cylinder axis and the distance between them would then 
decrease further. A distance of 2 nm is rather close to the 
length of a hepta- or octapeptide in an extended confor- 
mation. If we allow for some bulging out of the polypep- 
tide chain, comparable to polypeptides bound to MHC 
molecules [31] somewhat larger stretches could be acco- 
modated. This could account for the heterogeneity in 
peptide length noted. 
In light of our results the existence of a molecular ruler 
in proteasomes seems likely. However, it may not neces- 
sarily be that the distance between active sites provides 
it. One could also envisage that properties of the binding 
groove determine the average length of the cleaved pep- 
tides. That is assuming that the binding strength per unit 
length is relatively low, the interaction of a relatively 
long peptide with an extended binding groove would be 
required for sufficiently high affinity to effect cleavage. 
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Peptides that are too short upstream or downstream of 
the scissile bond might have a small chance of becoming 
arrested; this could explain why cleavage does not pro- 
ceed beyond the size of the predominantly found pep- 
tides. 
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